This editorial looks to highlight the major advantages of MS in the clinical laboratory, explain the major hurdles in place and provide an insight into the potential applications for clinical biomarker analysis.
In this research article, the authors discuss how the use of LC–MS/MS could offer a viable alternative to immunoassays for the quantitation of endogenous glucagon, dosed glucagon and/or dosed GLP-1.
The authors discuss a disposable diagnostic biosensor for detecting and quantifying levels of cardiac tropinin-T from human serum.
This conference report, from the European Bioanalysis Forum Focus Workshop, Lisbon, Portugal, 9–10 June 2016, summarizes the essence from the conference discussions and from the proposals or conclusions made by all delegates on how to increase the necessary connectivity of the stakeholders involved in the bioanalysis of biomarkers.
In this commentary, the authors discuss test materials and study designs of method transfer studies for biotechnology products.
The following white paper outlines the critical aspects of biomarker specimen stability that are commonly encountered during clinical development
In this research article, the authors outlime the development and validation of electrochemilumiescence assays for quantification of α-synuclein, a putative biomarker for the diagnosis of Parkinson’s disease and related disorders.
In this study, a novel method was proposed to analyze free drug concentration and total drug concentration.
In this conference report from the 10th Global CRO council closed forum, the authors discuss scientific and regulatory issues specific to CROs within bioanalysis.
In this Methodology, the authors outline their use of capillary microsampling to collect smaller volumes of blood samples and the eliminated toxicokinetic satellite groups, during GLP toxicology studies.